Fifth Third Bancorp Lowers Position in Merck & Co., Inc. $MRK

Fifth Third Bancorp decreased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 588,969 shares of the company's stock after selling 11,563 shares during the period. Fifth Third Bancorp's holdings in Merck & Co., Inc. were worth $61,995,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. DLD Asset Management LP increased its holdings in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Jennison Associates LLC acquired a new position in Merck & Co., Inc. in the fourth quarter valued at $585,192,000. Invesco Ltd. grew its position in Merck & Co., Inc. by 16.6% during the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock valued at $1,665,585,000 after acquiring an additional 2,821,766 shares during the period. Ameriprise Financial Inc. grew its position in Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after acquiring an additional 2,735,459 shares during the period. Finally, Vanguard Group Inc. increased its stake in Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after acquiring an additional 2,185,853 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Insider Activity at Merck & Co., Inc.

In other news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the transaction, the insider directly owned 21,197 shares of the company's stock, valued at approximately $2,583,278.39. The trade was a 41.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP David Michael Williams sold 5,000 shares of the company's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president owned 30,838 shares of the company's stock, valued at $3,759,460.58. This trade represents a 13.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.17% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Barclays assumed coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an "overweight" rating and a $140.00 price objective on the stock. TD Cowen raised their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a "hold" rating in a report on Tuesday, January 20th. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Wolfe Research upgraded shares of Merck & Co., Inc. from a "peer perform" rating to an "outperform" rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. Finally, Cantor Fitzgerald increased their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $128.47.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $109.33 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a market capitalization of $270.03 billion, a price-to-earnings ratio of 15.02, a PEG ratio of 2.25 and a beta of 0.26. The business has a 50-day moving average of $117.69 and a 200-day moving average of $107.39.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company's revenue was up 4.9% on a year-over-year basis. During the same period last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts anticipate that Merck & Co., Inc. will post 4.89 EPS for the current fiscal year.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results and product momentum: Merck beat Q1 revenue and adjusted EPS expectations, driven by continued Keytruda demand and contributions from newer launches (Winrevair reported at ~$525M), which underpin near‑term revenue growth. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Management raised adjusted EPS guidance and emphasized oncology strength: Merck narrowed its 2026 guidance range but lifted its profit outlook on stronger Keytruda and new product trends, a positive for earnings power even as revenue bands were tightened. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Clinical pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — a near‑term clinical milestone that could add long‑term pipeline value if successful. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Calls and disclosures available: The full Q1 earnings call transcript and the investor slide deck are posted for deeper review of sales mix, margin drivers and forward guidance assumptions. Q1 2026 Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Minor analyst estimate moves: Some shops trimmed FY forecasts modestly (e.g., Erste’s slight EPS tweak), indicating traders are tweaking models but not overhauling consensus. MRK Q1 Earnings & Sales Beat; 2026 Sales View Tightened
• Negative Sentiment: One‑time acquisition charge produced a GAAP loss: Merck reported a quarterly loss driven by a Cidara‑related acquisition charge, which suppresses headline earnings and can weigh on near‑term sentiment. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Tighter revenue guidance and mixed product trends: Management narrowed the sales range for 2026 and flagged mixed growth among some newer and legacy products, which leaves upside constrained and raises uncertainty about sustained top‑line acceleration. Merck Q1 earnings beat; 2026 guidance narrowed
• Negative Sentiment: Market concerns about future sales erosion: Commentary and coverage highlighted risks from expected declines in certain legacy drugs (HPV vaccine, diabetes medicine) and the company’s efforts to offset those losses, which contributes to investor caution. Merck Stock Falls After Earnings

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.